Kentucky Legislature (healthcare bills) · April 14, 2026 · Primary source
KY SB 77: AN ACT relating to ibogaine research in the Commonwealth.
What the document says
Kentucky SB 77 creates new sections of KRS Chapter 218A to establish a legal and funding framework for ibogaine clinical research. The bill defines relevant terms and establishes the ibogaine research and intellectual property fund, to be administered by the Kentucky Department of Agriculture.
The fund's stated purpose is to allow the Department of Agriculture to enter a public-private partnership with a drug developer to conduct clinical drug development trial or trials related to the use of ibogaine for the treatment of opioid use disorder, co-occurring substance use disorder, or any other neurological or mental health condition for which ibogaine demonstrates efficacy.
The bill appropriates $21 million from the opioid abatement trust fund to the ibogaine research and intellectual property development fund, split across fiscal year 2026-2027 and fiscal year 2027-2028. The bill establishes requirements governing how the Department of Agriculture contracts with a drug developer regarding ibogaine research and intellectual property.
The bill was enacted as an emergency measure and was delivered to the Secretary of State as Acts Ch. 158. Ibogaine remains a Schedule I controlled substance under federal law, making FDA-regulated clinical trials the necessary pathway for the drug development activities this bill funds.
What this may mean
Drug developers entering public-private partnerships under this framework, as well as the Kentucky Department of Agriculture as the administering entity, may need to ensure clinical trial activities comply with FDA investigational new drug (IND) requirements and federal Controlled Substances Act scheduling obligations for Schedule I substances. Opioid abatement trust fund recipients and state compliance officers could require review of whether this appropriation is consistent with applicable opioid settlement fund use restrictions.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- Federal Register: DEA Diversion Decisions · June 9, 2026Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted TreatmentScore 100
- Kentucky Legislature (healthcare bills) · May 22, 2026KY HB 153: AN ACT relating to administrative regulations for medications for substance use disorder and declaring an emergency.Score 90
- California Medicaid Fraud Control Unit · May 4, 2026Attorney General Bonta Announces $7.4 Billion Purdue Pharma and Sackler Family Opioid Settlement Now in EffectScore 90
- FDA Press Announcements · June 16, 2026FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid OverdoseScore 86
- SAMHSA News · August 17, 2026HHS Awards Over $96 Million to Strengthen Mental Health, Suicide Prevention, and Substance Use Disorder ServicesScore 76
- Ohio Legislature (healthcare bills) · May 7, 2026OH SB 434: Enact the Verified Opioid and Intoxicant Consumer Ed (VOICE) ActScore 76